Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma

BACKGROUND: Ipilimumab is an approved immunotherapy that has shown an overall survival benefit in patients with cutaneous metastatic melanoma in two phase III trials. As results of registrational trials might not answer all questions regarding safety and efficacy of ipilimumab in patients with advan...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Transl Med
Autors principals: Zimmer, Lisa, Eigentler, Thomas K., Kiecker, Felix, Simon, Jan, Utikal, Jochen, Mohr, Peter, Berking, Carola, Kämpgen, Eckhart, Dippel, Edgar, Stadler, Rudolf, Hauschild, Axel, Fluck, Michael, Terheyden, Patrick, Rompel, Rainer, Loquai, Carmen, Assi, Zeinab, Garbe, Claus, Schadendorf, Dirk
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2015
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4635983/
https://ncbi.nlm.nih.gov/pubmed/26541511
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-015-0716-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars